
Advanced treatments of Neurobiological Modulation REAC-NPO and REAC-NPPO in the management of anxiety, depression and stress.

Depression, anxiety and stress are a symptomatic triad extremely widespread in contemporary society, capable of affecting both healthy subjects at particular stages of life and patients suffering from several concomitant diseases.. These disorders of mood, cognitive and neurovegetative function often result in marked psychosocial deterioration and significant disability.. In many cases, conventional therapeutic responses show limits of efficacy, especially when clinical pictures have refractory components or manifestations closely related to environmental stressors..
In the field of neuroscience and non-invasive neuromodulation techniques, research is constantly focused on identifying state-of-the-art therapeutic strategies that can optimise patients’ quality of life. In this scenario, the REAC technology (Radio Electric Asymmetric Conveyer), a technology platform designed for neurobiological and biological modulation.
A major scientific study published in the international peer-reviewed journal Neuropsychiatric Disease and Treatment assessed the effectiveness of specific REAC neuromodulation protocols in the simultaneous treatment of depression, anxiety and stress.
The research used the psychometric scale as a standardized measurement tool. DASS-42 (Depression Anxiety Stress Scale-42 items), a self-assessment questionnaire that independently and simultaneously quantifies the severity of the three negative emotional states.
The design of the study involved the comparison of two homogeneous populations by gender and age, evaluated at a distance of about 3 months:
The study group received two types of sequential treatment administered via the medical device. model BENE Mod 110 (Produced by ASMED, Florence, Italy):
The statistical analysis of the data, performed by Wilcoxon and Signs tests, detected highly significant changes (P< 0.05) exclusively in the REAC treatment group.
At baseline, the treated group showed average levels corresponding to mild severity for depression and anxiety, and moderate for stress.. At the second check, carried out about 3 months later, the average scores were standardized within the values of clinical normality:
| Analysed cluster (Treaty Group) | Average Pre-Treatment Score | Average Post-Treatment Score (3 months) | Clinical Status Reached |
| Depression | 14,253 (Lieve) | 7,593 | Normal |
| Anxiety | 11,423 (Lieve) | 5,319 | Normal |
| Stress | 17,577 (Moderate) | 9,615 | Normal |
In contrast, there were no clinically or statistically relevant changes between the first and second measurements in the untreated control group (mean depression values increased from 12,648 to 12,868; anxiety from 11,786 to 10,412; stress from 16,582 to 15,934).
Population distribution graphs (Gaussian curves) indicate a marked shift of treated patients towards the lowest levels of severity and a progressive concentration in the ranges of psychometric normality..

Unlike other methods of transcranial stimulation operating on brain tissue — such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) — REAC technology is not based on the generation of localised electrical hyper- or hypo-polarisation phenomena..
Safety Profile Note
The REAC-NPO and REAC-NPPO protocols have highlighted a high safety profile. Therapeutic sessions have proven well tolerated Patients, with an minimal discomfort and a total absence of undesirable side effects or adverse reactions recorded in clinical practice. Extremely fast administration times facilitate the integration of these protocols into normal outpatient activities.
As an intrinsic limit of the method compared to home pharmacological treatments, it should be noted that REAC protocols cannot be self-administered by the patient and require the use of professional devices managed by qualified medical personnel..
The clinical results analyzed confirm that the Neurobiological Modulation treatments REAC-NPO and REAC-NPPO represent efficient and clinically tested tools for the therapeutic management of manifestations related to stress, anxiety and depression. Thanks to the speed of execution and the absence of systemic side effects, this technology is a valuable support for neuropsychophysical optimisation projects and for the overall improvement of the patient’s quality of life.
The information contained in this article is provided for informational and informative purposes only and is based on the published scientific evidence cited in the source. They do not intend in any way to replace the opinion, diagnosis or treatment plan of the attending physician. You are always invited to consult a specialist doctor to assess the clinical suitability and application of the therapeutic protocols described.
The study is available on PubMed: https://pubmed.ncbi.nlm.nih.gov/30858704/


